WDN/DC:dm 03/04/05 6235-69895-01 360608

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ryuichi Morishita & Munchisa Shimamura

Application No. 10/517,154

Filed: December 6, 2004

Confirmation No. 2664

AGENTS FOR GENE THERAPY OF For:

CEREBROVASCULAR DISORDERS

Examiner: Not yet assigned

Art Unit: 1642

Attorney Reference No. 6235-69895-01

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attomey for Applicant(s)

Date Mailed _ March 4, 2005

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several Englishlanguage and non-English-language documents. The relevance of the non-English-language documents that are enclosed is described in the English-language translation attached to each document. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of the references listed on the accompanying PTO-1449 that were cited in an International Search Report for corresponding International Application No. PCT/JP03/07004 are not enclosed because copies should have been provided directly to the USPTO by WIPO under an exchange program between the USPTO and the Japanese Patent Office. However, Applicants will provide copies of such references upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


David Cash, Ph.D.

Registration No. 52,706

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc: Docketing





| Attorney Docket Number | 6235-69895-01 |
|------------------------|-------------------------|
| Application Number | 10/517,154 |
| Filing Date | December 6, 2004 |
| First Named Inventor | Morishita |
| Art Unit | 1642 |
| Examiner Name | Not yet assigned. Noble |

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

| Examiner's Initials* | Cite No. (optional) | Number | Publication Date | Name of Applicant or Patentee |
|-------------------------|------------------------|--------|------------------|-------------------------------|
| | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Country | Number | Publication Date | Name of Applicant or Patentee |
|-------------------------|------------------------|---|--|------------------|-------------------------------|
| MN | | Europe | 1132098 A1 | 09/12/2001 | MedGene Bioscience, Inc. |
| | | Europe | 722737 A1 | 07/24/1996 | Sumitomo Pharmaceuticals Co. |
| | | Europe | 1170363 A1 | 01/09/2002 | Kaneda, Yasufumi |
| | | WIPO | WO 01/26694 A1 (w/English Translation) | 04/19/2001 | MedGene Bioscience, Inc. |
| | | WIPO | WO 01/32220 A1 (w/English Translation) | 05/10/2001 | MedGene Bioscience, Inc. |
| MN | | WIPO | WO 02/089854 A1 (w/English Translation) | 11/14/2002 | Anges Mg, Inc. |
| Examiner's Initials* | Cite No. (optional) | OTHER DOCUMENTS | | | |
| MN | | Hayashi et al., "Gene Therapy for Preventing Neuronal Death Using Hepatocyte Growth Factor: In Vivo Gene Transfer of HGF to Subarachnoid Space Prevents Delayed Neuronal Death in Gerbil Hippocampal CA1 Neurons," Gene Ther. 8:1167-1173 (2001). | | | |
| MN | | Ishida et al., "Nokosoku (Nokyoketsu) ni Taisuru Idenshi Chiryo, Noshinkei," 2002 March, Vol. 54, No. 3, pages 213 to 219. | | | |
| | | | | | |
| | | | | | |

| EXAMINER Marcia Discuss sources to some 5 to the Company of the Co | /Marcia Noble/ | DATE CONSIDERED: | 11/11/2006 |
|--|----------------|---------------------|------------|
| 0.110510 | | | |

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.